Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Gemcitabine + Cisplatin Neoadjuvant Therapy in MIBC
NCT02690558Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2016
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in bladder cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Percentage of Subjects That Reach Pathological Downstaging (<pT2) at the Time of Cystectomy. Started May 2016; status: completed.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02690558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690558.